Innate Pharma S.A.
IPHA • Biotechnology
$0.00
— 0.00 (0.00%)
EarningsLatest report: Jun 30, 2026
WEAK PROFILEWeakConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Weak historical ratio profile. The current evidence does not support a favorable risk/reward view.
Market Cap
$179.36M
Growth
-5.0%
Cash Flow
0/5
Trend
Negative
Evidence
Negative growth trendWeak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Sep 18, 2026, 12:06 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$0.00
Change0.00%
Market Cap$179.36M
52W Range1.17 - 2.71
Beta0.88
Gross Margin100.00%
Oper. Margin-19.17%
Profit Margin-17.65%
Debt/Eq-1.04
Current Ratio1.27
Quick Ratio1.27
Revenue 5Y-5.02%
Price$0.00
Change0.00%
Market Cap$179.36M
52W Range1.17 - 2.71
Beta0.88
Gross Margin100.00%
Oper. Margin-19.17%
Profit Margin-17.65%
Debt/Eq-1.04
Current Ratio1.27
Quick Ratio1.27
Revenue 5Y-5.02%
Target$6.67
Target Median$7.00
Target Range4.00 - 9.00
Volume185.71K
Avg Volume145.09K
EPS Surprise-0.19
Investment DNA
How strong this company looks for long-term investors
26
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
57/100
Growth Potential
Revenue and expansion
20/100
Price Attractiveness
Cheap or expensive today
20/100
Why this score▼
Negative growth trendWeak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
No vote count available
Bullish
0
Hold
0
Bearish
0
Price Target
2026-09-18
Low
$4.00
Mean
$6.67
Median
$7.00
High
$9.00
🧾
No insider activity
No recent insider transactions available.